The National Pharmaceutical Pricing Authority (NPPA) on September 10, 2026, determined the retail price of the formulation containing Gentamicin Sulphate IP equivalent to Gentamicin base 0.3% w/v + Dexamethasone Sodium Phosphate IP equivalent to Dexamethasone Phosphate 0.1% w/v, along with Sodium Methylparaben 0.05% w/v and Sodium Propylparaben 0.01% w/v as preservatives, for M/s Skymap Pharmaceuticals Pvt. Ltd. (Manufacturer) and M/s Wellgen Medicare LLP (Marketer) under the Drugs (Prices Control) Order, 2013.
Based on the January 2026 market data, the price calculation considered various brands of the same formulation, including Glycort products marketed by Torque Pharmaceuticals Pvt. Ltd. The calculation takes into account market share, MAT value, PTR and number of packs considered. The worked-out retail price is ₹1.75 per ml, excluding GST, and the proposed retail price is also ₹1.75 per ml, excluding GST, after adding the prescribed 16% retailer margin.
Accordingly, the retail price for the specified formulation has been proposed at ₹1.75 per ml excluding GST under the price determination mechanism of DPCO, 2013. The matter is relevant to the concerned pharmaceutical manufacturer and marketer and their compliance with the retail price determined by NPPA.
[File No. 19(5312)/2026/DP/NPPA/Div.II]
